DHEA – why it is especially important for menopausal women
DHEA(S) levels across the lifespan
![](/images/sex-steroid-levels-aging-men-women.gif)
Can DHEA supplementation help women suffering from menopausal symptoms?
DHEA vs. traditional HRT
DHEA dose considerations
Summary
References:
1. Baulieu, E.E., et al., An Adrenal-Secreted "Androgen": Dehydroisoandrosterone Sulfate. Its Metabolism and a Tentative Generalization on the Metabolism of Other Steroid Conjugates in Man. Recent Prog Horm Res, 1965. 21: p. 411-500.
2. Feldman, H.A., et al., Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab, 2002. 87(2): p. 589-98.
3. Harman, S.M., et al., Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab, 2001. 86(2): p. 724-31.
4. Orentreich, N., et al., Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab, 1984. 59(3): p. 551-5.
5. Orentreich, N., et al., Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab, 1992. 75(4): p. 1002-4.
6. Labrie, F., et al., Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab, 1997. 82(8): p. 2396-402.
7. Migeon, C.J., et al., Dehydroepiandrosterone and androsterone levels in human plasma: effect of age and sex; day-to-day and diurnal variations. J Clin Endocrinol Metab, 1957. 17(9): p. 1051-62.
8. Labrie, F., DHEA, important source of sex steroids in men and even more in women. Prog Brain Res, 2010. 182: p. 97-148.
9. Utian, W.H., Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes, 2005. 3: p. 47.
10. Hemminki, E., et al., Variability of bothersome menopausal symptoms over time--a longitudinal analysis using the Estonian postmenopausal hormone therapy trial (EPHT). BMC Womens Health, 2012. 12: p. 44.
11. Gold, E.B., et al., Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol, 2000. 152(5): p. 463-73.
12. Labrie, F., Impact of circulating dehydroepiandrosterone on androgen formation in women. Menopause, 2011. 18(5): p. 471-3.
13. Labrie, F., C. Martel, and J. Balser, Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary? Menopause, 2011. 18(1): p. 30-43.
14. Genazzani, A.R., et al., Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric, 2011. 14(6): p. 661-8.
15. Stomati, M., et al., Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Gynecol Endocrinol, 2000. 14(5): p. 342-63.
16. Schmidt, P.J., et al., Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry, 2005. 62(2): p. 154-62.
17. Genazzani, A.D., et al., Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. Fertil Steril, 2003. 80(6): p. 1495-501.
18. Labrie, F., et al., Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause, 2009. 16(5): p. 907-22.
19. Stomati, M., et al., Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women. Gynecol Endocrinol, 1999. 13(1): p. 15-25.
20. Genazzani, A.R., et al., Long-term low-dose oral administration of dehydroepiandrosterone modulates adrenal response to adrenocorticotropic hormone in early and late postmenopausal women. Gynecol Endocrinol, 2006. 22(11): p. 627-35.
21. Pluchino, N., et al., One-year therapy with 10mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu. Maturitas, 2008. 59(4): p. 293-303.
22. Brinton, R.D., Neurosteroids as regenerative agents in the brain: therapeutic implications. Nat Rev Endocrinol, 2013. 9(4): p. 241-50.
23. Maninger, N., et al., Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Front Neuroendocrinol, 2009. 30(1): p. 65-91.
24. Melcangi, R.C. and G.C. Panzica, Allopregnanolone: state of the art. Prog Neurobiol, 2014. 113: p. 1-5.
25. Robel, P. and E.E. Baulieu, Neurosteroids Biosynthesis and function. Trends Endocrinol Metab, 1994. 5(1): p. 1-8.
26. Schule, C., C. Nothdurfter, and R. Rupprecht, The role of allopregnanolone in depression and anxiety. Prog Neurobiol, 2014. 113: p. 79-87.
27. Mellon, S.H., Neurosteroids: biochemistry, modes of action, and clinical relevance. J Clin Endocrinol Metab, 1994. 78(5): p. 1003-8.
28. Majewska, M.D., Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance. Prog Neurobiol, 1992. 38(4): p. 379-95.
29. Baulieu, E.E., Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Recent Prog Horm Res, 1997. 52: p. 1-32.
30. Backstrom, T., et al., Allopregnanolone and mood disorders. Prog Neurobiol, 2014. 113: p. 88-94.
31. Brot, M.D., et al., The anxiolytic-like effects of the neurosteroid allopregnanolone: interactions with GABA(A) receptors. Eur J Pharmacol, 1997. 325(1): p. 1-7.
32. Hanson, S.M. and C. Czajkowski, Structural mechanisms underlying benzodiazepine modulation of the GABA(A) receptor. J Neurosci, 2008. 28(13): p. 3490-9.
33. Benarroch, E.E., Endogenous opioid systems: current concepts and clinical correlations. Neurology, 2012. 79(8): p. 807-14.
34. Bodnar, R.J., Endogenous opiates and behavior: 2012. Peptides, 2013. 50: p. 55-95.
35. Harber, V.J. and J.R. Sutton, Endorphins and exercise. Sports Med, 1984. 1(2): p. 154-71.
36. Gupta, B., et al., A Comparative Study of CEE, Tibolone, and DHEA as Hormone Replacement Therapy for Surgical Menopause. J Obstet Gynaecol India, 2013. 63(3): p. 194-8.